SCHEMBL320538

SCHEMBL320538

COc1ccc(C(F)(F)F)cc1-c1cc(Cl)nnc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.41
PDE10A Q9Y233 1/20 0.41
CETP P11597 4/20 0.39
CRHR1 P34998 1/20 0.38
PDE5A O76074 1/20 0.38
SCD O00767 1/20 0.38
LRRK2 Q5S007 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PTGDR2 Q9Y5Y4 3/20 0.36
CYP2C9 P11712 2/20 0.36
CYP3A4 P08684 1/20 0.36
TBXA2R P21731 1/20 0.36
PTGIR P43119 1/20 0.36
PTGDR Q13258 1/20 0.36
TP53 P04637 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
KCNQ4 P56696 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320158 0.79 PDE2A (0.42) PDE2APDE10ACETPCRHR1RAB9A
SCHEMBL31309237 0.77 CRHR1 (0.45) CRHR1LRRK2
SCHEMBL10147885 0.73 NOTUM (0.43) PDE2APDE10ACETPL3MBTL1PTGDR2
SCHEMBL26093033 0.73 CRHR1 (0.52) PDE2APDE10ACRHR1LRRK2
SCHEMBL30374587 0.73 CRHR1 (0.52) PDE2APDE10ACRHR1LRRK2
SCHEMBL18618128 0.72 MAPT (0.43) CETPMAPTPTGDR2CYP2C9CYP3A4
SCHEMBL29276868 0.71 CFTR (0.46) CETPPDE5ALRRK2MAPTPTGDR2
SCHEMBL31006699 0.71 CFTR (0.46) CETPPDE5ALRRK2MAPTPTGDR2
SCHEMBL10451549 0.71 MEN1 (0.53) MAPTRAB9AL3MBTL1CYP2C9CYP3A4
SCHEMBL24072859 0.70 CTSA (0.49) LRRK2MAPTRAB9ACTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109667-A1 Chemical Compounds SCN1A, SCN7A, SCN1B PDE2A 1508/4885PDE10A 430/4885CETP 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.